The therapeutic effect of glycosaminoglycan polysulfuric acid ester (GAGPS) was studied using the Pond-Nuki model of canine osteoarthritis. The clinical setting was simulated by permitting 4 weeks ambulation without treatment, following anterior cruciate transection. Animals were then injected with GAGPS, 4 mg/kg intramuscularly, twice weekly during weeks 4-8. Control animals received intramuscular saline. The study was terminated 4 weeks after completion of the GAGPS or saline regimen (i.e., 12 weeks postoperatively). Cartilage from the medial femoral condyle was analyzed for collagen integrity (swelling properties), hydroxyproline, uronic acid, active and total proteoglycan (PG)-degrading metalloproteinase, PG-degrading serine proteinase, and histopathology (Mankin score). Condylar cartilage from animals treated with GAGPS demonstrated less cartilage swelling, less total and active metalloproteinase, and lower histopathologic scores Submitted for publication January 9, 1989; accepted in revised form May 30, 1989. than were found in cartilage from saline-treated animals. GAGPS was able to suppress PG-degrading enzyme activity and maintain a more normal-appearing cartilage. It is proposed that GAGPS suppressed PG breakdown by decreasing synthesis of metalloproteinase or by directly inhibiting metalloproteinase in cartilage, rather than by increasing synthesis of PG by chondrocytes.Osteoarthritis (OA) is a common disorder that affects over 40 million Americans (1). OA cartilage is characterized by loss of proteoglycan (PG), disruption of the collagen network, and eventual exposure of the underlying subchondral bone. Current therapy for patients with OA is primarily palliative and comprises a combination of physical, psychologic, surgical, and medicinal approaches, including the use of antiinflammatory agents. These measures have not been demonstrated to alter the progression of OA.There is a new avenue of research focusing on agents that can slow or reverse the progression of OA lesions. One prototypic agent that may alter cartilage degradation is glycosaminoglycan polysulfuric acid ester (GAGPS), an extract of bovine lung and tracheal tissue that has been sulfate-esterified and then purified. GAGPS has been found to stimulate GAG synthesis in vitro (2), inhibit collagen and PG catabolism (3), and inhibit several enzymes, such as hyaluronidase, cathepsin B 1, elastase, collagenase, and a neutral metalloproteinase that degrades PGs (3,4).Matrix proteoglycans play an important role in the structural integrity of cartilage. Mankin et a1 (5) and Ehrlich (6) found a loss of matrix PGs in cultured OA cartilage, which suggests degradative activity. Enzymes that can degrade PG at physiologic pH have